Novartis AG vs Super Micro Computer Inc — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Super Micro Computer Inc trades at $29.9 (market cap $15.41B). The key difference: Novartis AG is far larger — about 18.8× Super Micro Computer Inc's market cap, and Novartis AG pays a 3.17% dividend while Super Micro Computer Inc pays none. Which is the better fit depends on your goals.
| NVS | SMCI | |
|---|---|---|
Market Cap | $290.25B | $15.41B |
Sector | Health | Technology |
52-Week High | $168.62 | $60.71 |
52-Week Low | $113.50 | $20.53 |
Enterprise Value | $330.27B | $22.93B |
Dividend Yield | 3.17% | — |
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
Super Micro Computer (SMCI) trades at $23.83, down 1.41% on the day, with technical indicators showing bearish momentum despite recent positive earnings beats. The company reported strong Q1 2026 results with EPS of $0.84 beating expectations of $0.617, while preliminary Q4 guidance indicates significant margin expansion to 15-17% and over $60 billion in new orders. Valuation metrics remain attractive with P/E of 12.54 and P/S of 0.47, though cash flow trends show volatility with 2026 projections indicating operational challenges.
The outlook appears cautiously optimistic with analyst consensus price target of $36.71 representing 54% upside potential, though technical weakness and competitive pressures in AI hardware create near-term headwinds. Key risks include execution on massive order backlog, margin sustainability, and intense competition from Dell and HPE in the AI server market.
Trailing returns across standard periods
Latest headlines on both assets
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →Super Micro Computer, Inc., commonly known as Supermicro, is a leading provider of high-performance and high-efficiency server technology and innovation. The company specializes in designing, manufacturing, and selling advanced server, storage, and networking solutions, primarily for data centers, cloud computing, artificial intelligence, and 5G/Edge computing markets. SMCI's modular architecture allows for the rapid delivery of customized and purpose-built solutions, making it a key player in the enterprise computing and specialized AI infrastructure space.
Read more on SMCI →